{"transactions":[{"id":683474,"issuer":{"id":8157,"kind":"organization","name":"Aclarion, Inc."},"owners":[{"id":22219,"kind":"person","name":"Gould Gregory A","position":1,"cik":"0001252905","reported_name":"Gould Gregory A","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CFO"}}],"security":"Common Stock","published_at":"2026-08-18T12:30:03.000Z","date":"2026-08-14","kind":"purchase","planned":false,"acquired":true,"shares":10000,"price":2.45,"value":24500.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The Reporting Person purchased common stock on the public market on 08-14-2026."}],"balance_after":60000,"source":{"system":"sec-edgar","filing":"0001683168-26-006545","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1635077/000168316826006545/ownership.xml","form_type":"4"}},{"id":739792,"issuer":{"id":8157,"kind":"organization","name":"Aclarion, Inc."},"owners":[{"id":22219,"kind":"person","name":"Gould Gregory A","position":1,"cik":"0001252905","reported_name":"Gould Gregory A","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2026-06-12T20:30:42.000Z","date":"2026-06-11","kind":"grant","planned":false,"acquired":true,"shares":50000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The shares reported are restricted stock units (\"RSUs\") granted 6/11/2026 under the Company's equity incentive plan. Each RSU represents a contingent right to receive one share of ACON common stock."},{"field":"shares","element":"transactionShares","label":"F2","text":"100% of the RSUs shall vest on 6/1/2027. Any outstanding and unvested RSUs will also accelerate and fully vest upon a change of control (as defined in the Company's equity incentive plan)."}],"balance_after":50000,"source":{"system":"sec-edgar","filing":"0001683168-26-004813","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1635077/000168316826004813/ownership.xml","form_type":"4"}},{"id":1049594,"issuer":{"id":8157,"kind":"organization","name":"Aclarion, Inc."},"owners":[{"id":22219,"kind":"person","name":"Gould Gregory A","position":1,"cik":"0001252905","reported_name":"Gould Gregory A","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CFO"}}],"security":"Stock Option (right to buy)","published_at":"2025-09-03T21:10:03.000Z","date":"2025-09-02","kind":"grant","planned":false,"acquired":true,"shares":17000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option will vest 25% on September 2, 2026. The remaining 75% will vest thereafter in 36 equal monthly installments over the following three years."}],"balance_after":17000,"derivative":{"exercise_price":7.15,"expiration_date":"2035-09-02","underlying":"Common Stock","underlying_shares":17000},"source":{"system":"sec-edgar","filing":"0001683168-25-006662","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1635077/000168316825006662/ownership.xml","form_type":"4"}},{"id":2225113,"issuer":{"id":2770,"kind":"organization","name":"Charlotte's Web Holdings, Inc.","symbol":"CWBHF"},"owners":[{"id":22219,"kind":"person","name":"Gould Gregory A","position":1,"cik":"0001252905","reported_name":"Gould Gregory A","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (right to buy)","published_at":"2022-06-21T18:09:19.000Z","date":"2022-06-17","kind":"grant","acquired":true,"shares":1200000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option agreement provides that the option becomes exercisable in 2 equal annual installments beginning on 6/18/2023. The option was granted on 6/17/2022 in connection with Mr. Gould's appointment as an officer of the Company."}],"balance_after":1200000,"derivative":{"exercise_price":0.44,"expiration_date":"2032-06-17","underlying":"Common Shares","underlying_shares":1200000},"source":{"system":"sec-edgar","filing":"0001750155-22-000070","document":"wf-form4_165583494459513.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1252905/000175015522000070/wf-form4_165583494459513.xml","form_type":"4"}},{"id":2639174,"issuer":{"id":129046,"kind":"organization","name":"NewAge, Inc.","symbol":"NBEV"},"owners":[{"id":22219,"kind":"person","name":"Gould Gregory A","position":1,"cik":"0001252905","reported_name":"Gould Gregory A","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2021-07-07T22:18:30.000Z","date":"2021-07-02","kind":"tax_withholding","acquired":false,"shares":73110,"price":2.24,"value":163766.4,"ownership":{"direct":true},"balance_after":331255,"source":{"system":"sec-edgar","filing":"0001493152-21-016394","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1252905/000149315221016394/ownership.xml","form_type":"4"}},{"id":2791486,"issuer":{"id":129046,"kind":"organization","name":"NewAge, Inc.","symbol":"NBEV"},"owners":[{"id":22219,"kind":"person","name":"Gould Gregory A","position":1,"cik":"0001252905","reported_name":"Gould Gregory A","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2021-03-12T22:23:35.000Z","date":"2021-03-10","kind":"grant","acquired":true,"shares":125000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Option vests on July 2, 2021."}],"balance_after":125000,"derivative":{"exercise_price":2.79,"expiration_date":"2024-03-10","underlying":"Common Stock","underlying_shares":125000},"source":{"system":"sec-edgar","filing":"0001493152-21-005923","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1252905/000149315221005923/ownership.xml","form_type":"4"}},{"id":2919601,"issuer":{"id":129046,"kind":"organization","name":"NewAge, Inc.","symbol":"NBEV"},"owners":[{"id":22219,"kind":"person","name":"Gould Gregory A","position":1,"cik":"0001252905","reported_name":"Gould Gregory A","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2021-01-06T02:13:32.000Z","date":"2021-01-05","kind":"tax_withholding","acquired":false,"shares":26507,"price":2.63,"value":69713.41,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"In accordance with the 2016-2017 Long-Term Incentive Plan (\"Plan\") of NewAge, Inc. (the \"Company\"), the Reporting Person returned shares of the Company's common stock to the Company to pay the Reporting Person's withholding taxes due upon the vesting of restricted shares of common stock previously awarded to the Reporting Person under the Plan on July 1, 2019."}],"balance_after":404365,"source":{"system":"sec-edgar","filing":"0001493152-21-000251","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1252905/000149315221000251/ownership.xml","form_type":"4"}},{"id":2948287,"issuer":{"id":129046,"kind":"organization","name":"NewAge, Inc.","symbol":"NBEV"},"owners":[{"id":22219,"kind":"person","name":"Gould Gregory A","position":1,"cik":"0001252905","reported_name":"Gould Gregory A","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2020-12-12T00:06:31.000Z","date":"2020-12-10","kind":"tax_withholding","acquired":false,"shares":9564,"price":3.16,"value":30222.24,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"In accordance with the 2019 Equity Incentive Plan (\"Plan\") of NewAge, Inc. (the \"Company\"), the Reporting Person returned shares of the Company's common stock to the Company to pay the Reporting Person's withholding taxes due upon the vesting of restricted shares of common stock previously awarded to the Reporting Person under the Plan on December 10, 2019."}],"balance_after":430872,"source":{"system":"sec-edgar","filing":"0001493152-20-023426","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1252905/000149315220023426/ownership.xml","form_type":"4"}},{"id":2999924,"issuer":{"id":129046,"kind":"organization","name":"NewAge, Inc.","symbol":"NBEV"},"owners":[{"id":22219,"kind":"person","name":"Gould Gregory A","position":1,"cik":"0001252905","reported_name":"Gould Gregory A","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2020-10-26T21:09:51.000Z","date":"2020-10-22","kind":"tax_withholding","acquired":false,"shares":9564,"price":2.72,"value":26014.08,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"In accordance with the 2019 Equity Incentive Plan (\"Plan\") of NewAge, Inc. (the \"Company\"), the Reporting Person returned shares of the Company's common stock to the Company to pay the Reporting Person's withholding taxes due upon the vesting of restricted shares of common stock previously awarded to the Reporting Person under the Plan on July 1, 2019."}],"balance_after":440436,"source":{"system":"sec-edgar","filing":"0001493152-20-019963","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1252905/000149315220019963/ownership.xml","form_type":"4"}},{"id":3343516,"issuer":{"id":129046,"kind":"organization","name":"NewAge, Inc.","symbol":"NBEV"},"owners":[{"id":22219,"kind":"person","name":"Gould Gregory A","position":1,"cik":"0001252905","reported_name":"Gould Gregory A","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2019-12-12T23:03:54.000Z","date":"2019-12-10","kind":"grant","acquired":true,"shares":100000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The option vests as follows: 33% on December 10, 2020, 33% on December 10, 2021 and 34% on December 10, 2022."}],"balance_after":100000,"derivative":{"exercise_price":1.83,"expiration_date":"2029-12-10","underlying":"Common Stock","underlying_shares":100000},"source":{"system":"sec-edgar","filing":"0001493152-19-019124","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1252905/000149315219019124/ownership.xml","form_type":"4"}},{"id":3343515,"issuer":{"id":129046,"kind":"organization","name":"NewAge, Inc.","symbol":"NBEV"},"owners":[{"id":22219,"kind":"person","name":"Gould Gregory A","position":1,"cik":"0001252905","reported_name":"Gould Gregory A","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2019-12-12T23:03:54.000Z","date":"2019-12-10","kind":"grant","acquired":true,"shares":100000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"On December 10, 2019, New Age Beverages Corporation (the \"Company\") issued 100,000 restricted shares of the Company's common stock (\"Common Stock\") to Mr. Gould. The Common Stock vests as follows: 33% on December 10, 2020, 33% on December 10, 2021 and 34% on December 10, 2022."}],"balance_after":450000,"source":{"system":"sec-edgar","filing":"0001493152-19-019124","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1252905/000149315219019124/ownership.xml","form_type":"4"}},{"id":3467674,"issuer":{"id":129046,"kind":"organization","name":"NewAge, Inc.","symbol":"NBEV"},"owners":[{"id":22219,"kind":"person","name":"Gould Gregory A","position":1,"cik":"0001252905","reported_name":"Gould Gregory A","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CFO"}}],"security":"Stock Option (right to buy)","published_at":"2019-07-03T20:20:47.000Z","date":"2019-07-01","kind":"grant","acquired":true,"shares":100000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"On July 1, 2019, the Company issued to Mr. Gould an option (the \"Option\") to purchase 100,000 shares of the Company's Common Stock at a purchase price of $4.75, representing the closing price of the Common Stock on the date of grant. The Option was issued pursuant to the terms of his employment letter dated October 3, 2018 with the Company and vests as follows: 33% on December 15, 2019, 33% on December 15, 2020 and 34% on December 15, 2021."}],"balance_after":100000,"derivative":{"exercise_price":4.75,"expiration_date":"2029-07-01","underlying":"Common Stock","underlying_shares":100000},"source":{"system":"sec-edgar","filing":"0001213900-19-012063","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1252905/000121390019012063/ownership.xml","form_type":"4"}},{"id":3467673,"issuer":{"id":129046,"kind":"organization","name":"NewAge, Inc.","symbol":"NBEV"},"owners":[{"id":22219,"kind":"person","name":"Gould Gregory A","position":1,"cik":"0001252905","reported_name":"Gould Gregory A","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CFO"}}],"security":"Common Stock","published_at":"2019-07-03T20:20:47.000Z","date":"2019-07-01","kind":"grant","acquired":true,"shares":250000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"On July 1, 2019, the Company issued 250,000 restricted shares of the Company's Common Stock to Mr. Gould. The Common Stock was issued pursuant to the terms of his employment letter dated October 3, 2018 with the Company and vests as follows: 33% on January 2, 2020, 33% on January 2, 2021 and 34% on January 2, 2022."}],"balance_after":350000,"source":{"system":"sec-edgar","filing":"0001213900-19-012063","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1252905/000121390019012063/ownership.xml","form_type":"4"}},{"id":3467672,"issuer":{"id":129046,"kind":"organization","name":"NewAge, Inc.","symbol":"NBEV"},"owners":[{"id":22219,"kind":"person","name":"Gould Gregory A","position":1,"cik":"0001252905","reported_name":"Gould Gregory A","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CFO"}}],"security":"Common Stock","published_at":"2019-07-03T20:20:47.000Z","date":"2019-07-01","kind":"grant","acquired":true,"shares":100000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"On July 1, 2019, New Age Beverages Corporation (the \"Company\") issued 100,000 restricted shares of the Company's common stock (\"Common Stock\") to Mr. Gould. The Common Stock was issued pursuant to the terms of his employment letter dated October 3, 2018 with the Company and vests as follows: 33% on October 22, 2019, 33% on October 22, 2020 and 34% on October 22, 2021."}],"balance_after":100000,"source":{"system":"sec-edgar","filing":"0001213900-19-012063","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1252905/000121390019012063/ownership.xml","form_type":"4"}},{"id":3485441,"issuer":{"id":5856,"kind":"organization","name":"CytoDyn Inc."},"owners":[{"id":22219,"kind":"person","name":"Gould Gregory A","position":1,"cik":"0001252905","reported_name":"Gould Gregory A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Options (right to buy)","published_at":"2019-06-20T00:58:17.000Z","date":"2019-06-18","kind":"grant","acquired":true,"shares":100000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The options will vest in four equal quarterly installments, commencing on September 1, 2019."}],"balance_after":100000,"derivative":{"exercise_price":0.52,"expiration_date":"2029-06-18","underlying":"Common Stock","underlying_shares":100000},"source":{"system":"sec-edgar","filing":"0000899243-19-017505","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1175680/000089924319017505/doc4.xml","form_type":"4"}},{"id":3760348,"issuer":{"id":5856,"kind":"organization","name":"CytoDyn Inc."},"owners":[{"id":22219,"kind":"person","name":"Gould Gregory A","position":1,"cik":"0001252905","reported_name":"Gould Gregory A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Options (right to buy)","published_at":"2018-11-19T13:01:46.000Z","date":"2018-11-16","kind":"grant","acquired":true,"shares":100000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On November 16, 2018, CytoDyn Inc. completed a holding company reorganization in which CytoDyn Inc. (\"Old CytoDyn\") merged with and into a wholly-owned subsidiary of Point NewCo Inc. (which has been renamed CytoDyn Inc.) (\"New CytoDyn\") with Old CytoDyn continuing as the surviving corporation and as a wholly-owned subsidiary of New CytoDyn (the \"Holding Company Reorganization\"). In the Holding Company Reorganization, each outstanding share of Old CytoDyn capital stock (including common stock and Series B preferred stock) was disposed of in exchange for an equivalent share of New CytoDyn capital stock, and each Old CytoDyn warrant, convertible promissory note and stock option was converted into an equivalent right to purchase New CytoDyn common stock."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"In connection with the transactions consummated on November 16, 2018, immediately after the effective time of the Holding Company Reorganization, New CytoDyn issued to ProstaGene, LLC 27,000,000 newly issued shares of New CytoDyn common stock (representing approximately 6.5% of the total number of outstanding shares of New CytoDyn common stock, after giving effect to such issuance)."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The options (including predecessor options) vest in four equal quarterly installments commencing on September 1, 2018."}],"balance_after":100000,"derivative":{"exercise_price":0.49,"expiration_date":"2028-06-08","underlying":"Common Stock","underlying_shares":100000},"source":{"system":"sec-edgar","filing":"0000899243-18-029257","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/1175680/000089924318029257/doc4.xml","form_type":"4"}},{"id":3760347,"issuer":{"id":5856,"kind":"organization","name":"CytoDyn Inc."},"owners":[{"id":22219,"kind":"person","name":"Gould Gregory A","position":1,"cik":"0001252905","reported_name":"Gould Gregory A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Options (right to buy)","published_at":"2018-11-19T13:01:46.000Z","date":"2018-11-16","kind":"grant","acquired":true,"shares":50000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On November 16, 2018, CytoDyn Inc. completed a holding company reorganization in which CytoDyn Inc. (\"Old CytoDyn\") merged with and into a wholly-owned subsidiary of Point NewCo Inc. (which has been renamed CytoDyn Inc.) (\"New CytoDyn\") with Old CytoDyn continuing as the surviving corporation and as a wholly-owned subsidiary of New CytoDyn (the \"Holding Company Reorganization\"). In the Holding Company Reorganization, each outstanding share of Old CytoDyn capital stock (including common stock and Series B preferred stock) was disposed of in exchange for an equivalent share of New CytoDyn capital stock, and each Old CytoDyn warrant, convertible promissory note and stock option was converted into an equivalent right to purchase New CytoDyn common stock."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"In connection with the transactions consummated on November 16, 2018, immediately after the effective time of the Holding Company Reorganization, New CytoDyn issued to ProstaGene, LLC 27,000,000 newly issued shares of New CytoDyn common stock (representing approximately 6.5% of the total number of outstanding shares of New CytoDyn common stock, after giving effect to such issuance)."}],"balance_after":50000,"derivative":{"exercise_price":0.8,"exercise_date":"2018-02-15","expiration_date":"2023-02-15","underlying":"Common Stock","underlying_shares":50000},"source":{"system":"sec-edgar","filing":"0000899243-18-029257","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1175680/000089924318029257/doc4.xml","form_type":"4"}},{"id":3760346,"issuer":{"id":5856,"kind":"organization","name":"CytoDyn Inc."},"owners":[{"id":22219,"kind":"person","name":"Gould Gregory A","position":1,"cik":"0001252905","reported_name":"Gould Gregory A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Options (right to buy)","published_at":"2018-11-19T13:01:46.000Z","date":"2018-11-16","kind":"grant","acquired":true,"shares":160662,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On November 16, 2018, CytoDyn Inc. completed a holding company reorganization in which CytoDyn Inc. (\"Old CytoDyn\") merged with and into a wholly-owned subsidiary of Point NewCo Inc. (which has been renamed CytoDyn Inc.) (\"New CytoDyn\") with Old CytoDyn continuing as the surviving corporation and as a wholly-owned subsidiary of New CytoDyn (the \"Holding Company Reorganization\"). In the Holding Company Reorganization, each outstanding share of Old CytoDyn capital stock (including common stock and Series B preferred stock) was disposed of in exchange for an equivalent share of New CytoDyn capital stock, and each Old CytoDyn warrant, convertible promissory note and stock option was converted into an equivalent right to purchase New CytoDyn common stock."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"In connection with the transactions consummated on November 16, 2018, immediately after the effective time of the Holding Company Reorganization, New CytoDyn issued to ProstaGene, LLC 27,000,000 newly issued shares of New CytoDyn common stock (representing approximately 6.5% of the total number of outstanding shares of New CytoDyn common stock, after giving effect to such issuance)."}],"balance_after":160662,"derivative":{"exercise_price":0.56,"exercise_date":"2018-02-07","expiration_date":"2028-02-07","underlying":"Common Stock","underlying_shares":160662},"source":{"system":"sec-edgar","filing":"0000899243-18-029257","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1175680/000089924318029257/doc4.xml","form_type":"4"}},{"id":3760345,"issuer":{"id":5856,"kind":"organization","name":"CytoDyn Inc."},"owners":[{"id":22219,"kind":"person","name":"Gould Gregory A","position":1,"cik":"0001252905","reported_name":"Gould Gregory A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Options (right to buy)","published_at":"2018-11-19T13:01:46.000Z","date":"2018-11-16","kind":"grant","acquired":true,"shares":75000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On November 16, 2018, CytoDyn Inc. completed a holding company reorganization in which CytoDyn Inc. (\"Old CytoDyn\") merged with and into a wholly-owned subsidiary of Point NewCo Inc. (which has been renamed CytoDyn Inc.) (\"New CytoDyn\") with Old CytoDyn continuing as the surviving corporation and as a wholly-owned subsidiary of New CytoDyn (the \"Holding Company Reorganization\"). In the Holding Company Reorganization, each outstanding share of Old CytoDyn capital stock (including common stock and Series B preferred stock) was disposed of in exchange for an equivalent share of New CytoDyn capital stock, and each Old CytoDyn warrant, convertible promissory note and stock option was converted into an equivalent right to purchase New CytoDyn common stock."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"In connection with the transactions consummated on November 16, 2018, immediately after the effective time of the Holding Company Reorganization, New CytoDyn issued to ProstaGene, LLC 27,000,000 newly issued shares of New CytoDyn common stock (representing approximately 6.5% of the total number of outstanding shares of New CytoDyn common stock, after giving effect to such issuance)."}],"balance_after":75000,"derivative":{"exercise_price":0.57,"exercise_date":"2018-09-01","expiration_date":"2027-06-01","underlying":"Common Stock","underlying_shares":75000},"source":{"system":"sec-edgar","filing":"0000899243-18-029257","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1175680/000089924318029257/doc4.xml","form_type":"4"}},{"id":3760344,"issuer":{"id":5856,"kind":"organization","name":"CytoDyn Inc."},"owners":[{"id":22219,"kind":"person","name":"Gould Gregory A","position":1,"cik":"0001252905","reported_name":"Gould Gregory A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Options (right to buy)","published_at":"2018-11-19T13:01:46.000Z","date":"2018-11-16","kind":"grant","acquired":true,"shares":100000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On November 16, 2018, CytoDyn Inc. completed a holding company reorganization in which CytoDyn Inc. (\"Old CytoDyn\") merged with and into a wholly-owned subsidiary of Point NewCo Inc. (which has been renamed CytoDyn Inc.) (\"New CytoDyn\") with Old CytoDyn continuing as the surviving corporation and as a wholly-owned subsidiary of New CytoDyn (the \"Holding Company Reorganization\"). In the Holding Company Reorganization, each outstanding share of Old CytoDyn capital stock (including common stock and Series B preferred stock) was disposed of in exchange for an equivalent share of New CytoDyn capital stock, and each Old CytoDyn warrant, convertible promissory note and stock option was converted into an equivalent right to purchase New CytoDyn common stock."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"In connection with the transactions consummated on November 16, 2018, immediately after the effective time of the Holding Company Reorganization, New CytoDyn issued to ProstaGene, LLC 27,000,000 newly issued shares of New CytoDyn common stock (representing approximately 6.5% of the total number of outstanding shares of New CytoDyn common stock, after giving effect to such issuance)."}],"balance_after":100000,"derivative":{"exercise_price":0.68,"exercise_date":"2017-11-17","expiration_date":"2026-11-17","underlying":"Common Stock","underlying_shares":100000},"source":{"system":"sec-edgar","filing":"0000899243-18-029257","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1175680/000089924318029257/doc4.xml","form_type":"4"}},{"id":3760343,"issuer":{"id":5856,"kind":"organization","name":"CytoDyn Inc."},"owners":[{"id":22219,"kind":"person","name":"Gould Gregory A","position":1,"cik":"0001252905","reported_name":"Gould Gregory A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Options (right to buy)","published_at":"2018-11-19T13:01:46.000Z","date":"2018-11-16","kind":"grant","acquired":true,"shares":50000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On November 16, 2018, CytoDyn Inc. completed a holding company reorganization in which CytoDyn Inc. (\"Old CytoDyn\") merged with and into a wholly-owned subsidiary of Point NewCo Inc. (which has been renamed CytoDyn Inc.) (\"New CytoDyn\") with Old CytoDyn continuing as the surviving corporation and as a wholly-owned subsidiary of New CytoDyn (the \"Holding Company Reorganization\"). In the Holding Company Reorganization, each outstanding share of Old CytoDyn capital stock (including common stock and Series B preferred stock) was disposed of in exchange for an equivalent share of New CytoDyn capital stock, and each Old CytoDyn warrant, convertible promissory note and stock option was converted into an equivalent right to purchase New CytoDyn common stock."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"In connection with the transactions consummated on November 16, 2018, immediately after the effective time of the Holding Company Reorganization, New CytoDyn issued to ProstaGene, LLC 27,000,000 newly issued shares of New CytoDyn common stock (representing approximately 6.5% of the total number of outstanding shares of New CytoDyn common stock, after giving effect to such issuance)."}],"balance_after":50000,"derivative":{"exercise_price":1.09,"exercise_date":"2017-06-01","expiration_date":"2026-06-01","underlying":"Common Stock","underlying_shares":50000},"source":{"system":"sec-edgar","filing":"0000899243-18-029257","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1175680/000089924318029257/doc4.xml","form_type":"4"}},{"id":3760342,"issuer":{"id":5856,"kind":"organization","name":"CytoDyn Inc."},"owners":[{"id":22219,"kind":"person","name":"Gould Gregory A","position":1,"cik":"0001252905","reported_name":"Gould Gregory A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Options (right to buy)","published_at":"2018-11-19T13:01:46.000Z","date":"2018-11-16","kind":"grant","acquired":true,"shares":50000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On November 16, 2018, CytoDyn Inc. completed a holding company reorganization in which CytoDyn Inc. (\"Old CytoDyn\") merged with and into a wholly-owned subsidiary of Point NewCo Inc. (which has been renamed CytoDyn Inc.) (\"New CytoDyn\") with Old CytoDyn continuing as the surviving corporation and as a wholly-owned subsidiary of New CytoDyn (the \"Holding Company Reorganization\"). In the Holding Company Reorganization, each outstanding share of Old CytoDyn capital stock (including common stock and Series B preferred stock) was disposed of in exchange for an equivalent share of New CytoDyn capital stock, and each Old CytoDyn warrant, convertible promissory note and stock option was converted into an equivalent right to purchase New CytoDyn common stock."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"In connection with the transactions consummated on November 16, 2018, immediately after the effective time of the Holding Company Reorganization, New CytoDyn issued to ProstaGene, LLC 27,000,000 newly issued shares of New CytoDyn common stock (representing approximately 6.5% of the total number of outstanding shares of New CytoDyn common stock, after giving effect to such issuance)."}],"balance_after":50000,"derivative":{"exercise_price":0.975,"exercise_date":"2016-09-01","expiration_date":"2025-06-01","underlying":"Common Stock","underlying_shares":50000},"source":{"system":"sec-edgar","filing":"0000899243-18-029257","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1175680/000089924318029257/doc4.xml","form_type":"4"}},{"id":3760341,"issuer":{"id":5856,"kind":"organization","name":"CytoDyn Inc."},"owners":[{"id":22219,"kind":"person","name":"Gould Gregory A","position":1,"cik":"0001252905","reported_name":"Gould Gregory A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Options (right to buy)","published_at":"2018-11-19T13:01:46.000Z","date":"2018-11-16","kind":"grant","acquired":true,"shares":25000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On November 16, 2018, CytoDyn Inc. completed a holding company reorganization in which CytoDyn Inc. (\"Old CytoDyn\") merged with and into a wholly-owned subsidiary of Point NewCo Inc. (which has been renamed CytoDyn Inc.) (\"New CytoDyn\") with Old CytoDyn continuing as the surviving corporation and as a wholly-owned subsidiary of New CytoDyn (the \"Holding Company Reorganization\"). In the Holding Company Reorganization, each outstanding share of Old CytoDyn capital stock (including common stock and Series B preferred stock) was disposed of in exchange for an equivalent share of New CytoDyn capital stock, and each Old CytoDyn warrant, convertible promissory note and stock option was converted into an equivalent right to purchase New CytoDyn common stock."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"In connection with the transactions consummated on November 16, 2018, immediately after the effective time of the Holding Company Reorganization, New CytoDyn issued to ProstaGene, LLC 27,000,000 newly issued shares of New CytoDyn common stock (representing approximately 6.5% of the total number of outstanding shares of New CytoDyn common stock, after giving effect to such issuance)."}],"balance_after":25000,"derivative":{"exercise_price":1.55,"exercise_date":"2013-06-01","expiration_date":"2022-06-01","underlying":"Common Stock","underlying_shares":25000},"source":{"system":"sec-edgar","filing":"0000899243-18-029257","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1175680/000089924318029257/doc4.xml","form_type":"4"}},{"id":3760340,"issuer":{"id":5856,"kind":"organization","name":"CytoDyn Inc."},"owners":[{"id":22219,"kind":"person","name":"Gould Gregory A","position":1,"cik":"0001252905","reported_name":"Gould Gregory A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Options (right to buy)","published_at":"2018-11-19T13:01:46.000Z","date":"2018-11-16","kind":"grant","acquired":true,"shares":50000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On November 16, 2018, CytoDyn Inc. completed a holding company reorganization in which CytoDyn Inc. (\"Old CytoDyn\") merged with and into a wholly-owned subsidiary of Point NewCo Inc. (which has been renamed CytoDyn Inc.) (\"New CytoDyn\") with Old CytoDyn continuing as the surviving corporation and as a wholly-owned subsidiary of New CytoDyn (the \"Holding Company Reorganization\"). In the Holding Company Reorganization, each outstanding share of Old CytoDyn capital stock (including common stock and Series B preferred stock) was disposed of in exchange for an equivalent share of New CytoDyn capital stock, and each Old CytoDyn warrant, convertible promissory note and stock option was converted into an equivalent right to purchase New CytoDyn common stock."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"In connection with the transactions consummated on November 16, 2018, immediately after the effective time of the Holding Company Reorganization, New CytoDyn issued to ProstaGene, LLC 27,000,000 newly issued shares of New CytoDyn common stock (representing approximately 6.5% of the total number of outstanding shares of New CytoDyn common stock, after giving effect to such issuance)."}],"balance_after":50000,"derivative":{"exercise_price":2,"exercise_date":"2012-08-08","expiration_date":"2021-08-08","underlying":"Common Stock","underlying_shares":50000},"source":{"system":"sec-edgar","filing":"0000899243-18-029257","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1175680/000089924318029257/doc4.xml","form_type":"4"}},{"id":3760339,"issuer":{"id":5856,"kind":"organization","name":"CytoDyn Inc."},"owners":[{"id":22219,"kind":"person","name":"Gould Gregory A","position":1,"cik":"0001252905","reported_name":"Gould Gregory A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Options (right to buy)","published_at":"2018-11-19T13:01:46.000Z","date":"2018-11-16","kind":"grant","acquired":true,"shares":50000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On November 16, 2018, CytoDyn Inc. completed a holding company reorganization in which CytoDyn Inc. (\"Old CytoDyn\") merged with and into a wholly-owned subsidiary of Point NewCo Inc. (which has been renamed CytoDyn Inc.) (\"New CytoDyn\") with Old CytoDyn continuing as the surviving corporation and as a wholly-owned subsidiary of New CytoDyn (the \"Holding Company Reorganization\"). In the Holding Company Reorganization, each outstanding share of Old CytoDyn capital stock (including common stock and Series B preferred stock) was disposed of in exchange for an equivalent share of New CytoDyn capital stock, and each Old CytoDyn warrant, convertible promissory note and stock option was converted into an equivalent right to purchase New CytoDyn common stock."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"In connection with the transactions consummated on November 16, 2018, immediately after the effective time of the Holding Company Reorganization, New CytoDyn issued to ProstaGene, LLC 27,000,000 newly issued shares of New CytoDyn common stock (representing approximately 6.5% of the total number of outstanding shares of New CytoDyn common stock, after giving effect to such issuance)."}],"balance_after":50000,"derivative":{"exercise_price":0.66,"exercise_date":"2015-06-01","expiration_date":"2019-06-01","underlying":"Common Stock","underlying_shares":50000},"source":{"system":"sec-edgar","filing":"0000899243-18-029257","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1175680/000089924318029257/doc4.xml","form_type":"4"}},{"id":3760338,"issuer":{"id":5856,"kind":"organization","name":"CytoDyn Inc."},"owners":[{"id":22219,"kind":"person","name":"Gould Gregory A","position":1,"cik":"0001252905","reported_name":"Gould Gregory A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2018-11-19T13:01:46.000Z","date":"2018-11-16","kind":"grant","acquired":true,"shares":19176,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On November 16, 2018, CytoDyn Inc. completed a holding company reorganization in which CytoDyn Inc. (\"Old CytoDyn\") merged with and into a wholly-owned subsidiary of Point NewCo Inc. (which has been renamed CytoDyn Inc.) (\"New CytoDyn\") with Old CytoDyn continuing as the surviving corporation and as a wholly-owned subsidiary of New CytoDyn (the \"Holding Company Reorganization\"). In the Holding Company Reorganization, each outstanding share of Old CytoDyn capital stock (including common stock and Series B preferred stock) was disposed of in exchange for an equivalent share of New CytoDyn capital stock, and each Old CytoDyn warrant, convertible promissory note and stock option was converted into an equivalent right to purchase New CytoDyn common stock."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"In connection with the transactions consummated on November 16, 2018, immediately after the effective time of the Holding Company Reorganization, New CytoDyn issued to ProstaGene, LLC 27,000,000 newly issued shares of New CytoDyn common stock (representing approximately 6.5% of the total number of outstanding shares of New CytoDyn common stock, after giving effect to such issuance)."}],"balance_after":19176,"source":{"system":"sec-edgar","filing":"0000899243-18-029257","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1175680/000089924318029257/doc4.xml","form_type":"4"}},{"id":3762697,"issuer":{"id":5856,"kind":"organization","name":"CytoDyn Inc."},"owners":[{"id":22219,"kind":"person","name":"Gould Gregory A","position":1,"cik":"0001252905","reported_name":"Gould Gregory A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Options (right to buy)","published_at":"2018-11-16T23:32:59.000Z","date":"2018-11-16","kind":"disposition_to_issuer","acquired":false,"shares":100000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On November 16, 2018, CytoDyn Inc. completed a holding company reorganization in which CytoDyn Inc. (\"Old CytoDyn\") merged with and into a wholly-owned subsidiary of Point NewCo Inc. (which has been renamed CytoDyn Inc.) (\"New CytoDyn\") with Old CytoDyn continuing as the surviving corporation and as a wholly-owned subsidiary of New CytoDyn (the \"Holding Company Reorganization\"). In the Holding Company Reorganization, each outstanding share of Old CytoDyn capital stock (including common stock and Series B preferred stock) was disposed of in exchange for an equivalent share of New CytoDyn capital stock, and each Old CytoDyn warrant, convertible promissory note and stock option was converted into an equivalent right to purchase New CytoDyn common stock."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"In connection with the transactions consummated on November 16, 2018, immediately after the effective time of the Holding Company Reorganization, New CytoDyn issued to ProstaGene, LLC 27,000,000 newly issued shares of New CytoDyn common stock (representing approximately 6.5% of the total number of outstanding shares of New CytoDyn common stock, after giving effect to such issuance)."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The options vest in four equal quarterly installments commencing on September 1, 2018."}],"balance_after":0,"derivative":{"exercise_price":0.49,"expiration_date":"2028-06-08","underlying":"Common Stock","underlying_shares":100000},"source":{"system":"sec-edgar","filing":"0000899243-18-029192","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/1175680/000089924318029192/doc4.xml","form_type":"4"}},{"id":3762696,"issuer":{"id":5856,"kind":"organization","name":"CytoDyn Inc."},"owners":[{"id":22219,"kind":"person","name":"Gould Gregory A","position":1,"cik":"0001252905","reported_name":"Gould Gregory A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Options (right to buy)","published_at":"2018-11-16T23:32:59.000Z","date":"2018-11-16","kind":"disposition_to_issuer","acquired":false,"shares":50000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On November 16, 2018, CytoDyn Inc. completed a holding company reorganization in which CytoDyn Inc. (\"Old CytoDyn\") merged with and into a wholly-owned subsidiary of Point NewCo Inc. (which has been renamed CytoDyn Inc.) (\"New CytoDyn\") with Old CytoDyn continuing as the surviving corporation and as a wholly-owned subsidiary of New CytoDyn (the \"Holding Company Reorganization\"). In the Holding Company Reorganization, each outstanding share of Old CytoDyn capital stock (including common stock and Series B preferred stock) was disposed of in exchange for an equivalent share of New CytoDyn capital stock, and each Old CytoDyn warrant, convertible promissory note and stock option was converted into an equivalent right to purchase New CytoDyn common stock."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"In connection with the transactions consummated on November 16, 2018, immediately after the effective time of the Holding Company Reorganization, New CytoDyn issued to ProstaGene, LLC 27,000,000 newly issued shares of New CytoDyn common stock (representing approximately 6.5% of the total number of outstanding shares of New CytoDyn common stock, after giving effect to such issuance)."}],"balance_after":0,"derivative":{"exercise_price":0.8,"exercise_date":"2018-02-15","expiration_date":"2023-02-15","underlying":"Common Stock","underlying_shares":50000},"source":{"system":"sec-edgar","filing":"0000899243-18-029192","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1175680/000089924318029192/doc4.xml","form_type":"4"}},{"id":3762695,"issuer":{"id":5856,"kind":"organization","name":"CytoDyn Inc."},"owners":[{"id":22219,"kind":"person","name":"Gould Gregory A","position":1,"cik":"0001252905","reported_name":"Gould Gregory A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Options (right to buy)","published_at":"2018-11-16T23:32:59.000Z","date":"2018-11-16","kind":"disposition_to_issuer","acquired":false,"shares":160662,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On November 16, 2018, CytoDyn Inc. completed a holding company reorganization in which CytoDyn Inc. (\"Old CytoDyn\") merged with and into a wholly-owned subsidiary of Point NewCo Inc. (which has been renamed CytoDyn Inc.) (\"New CytoDyn\") with Old CytoDyn continuing as the surviving corporation and as a wholly-owned subsidiary of New CytoDyn (the \"Holding Company Reorganization\"). In the Holding Company Reorganization, each outstanding share of Old CytoDyn capital stock (including common stock and Series B preferred stock) was disposed of in exchange for an equivalent share of New CytoDyn capital stock, and each Old CytoDyn warrant, convertible promissory note and stock option was converted into an equivalent right to purchase New CytoDyn common stock."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"In connection with the transactions consummated on November 16, 2018, immediately after the effective time of the Holding Company Reorganization, New CytoDyn issued to ProstaGene, LLC 27,000,000 newly issued shares of New CytoDyn common stock (representing approximately 6.5% of the total number of outstanding shares of New CytoDyn common stock, after giving effect to such issuance)."}],"balance_after":0,"derivative":{"exercise_price":0.56,"exercise_date":"2018-02-07","expiration_date":"2028-02-07","underlying":"Common Stock","underlying_shares":160662},"source":{"system":"sec-edgar","filing":"0000899243-18-029192","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1175680/000089924318029192/doc4.xml","form_type":"4"}},{"id":3762694,"issuer":{"id":5856,"kind":"organization","name":"CytoDyn Inc."},"owners":[{"id":22219,"kind":"person","name":"Gould Gregory A","position":1,"cik":"0001252905","reported_name":"Gould Gregory A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Options (right to buy)","published_at":"2018-11-16T23:32:59.000Z","date":"2018-11-16","kind":"disposition_to_issuer","acquired":false,"shares":75000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On November 16, 2018, CytoDyn Inc. completed a holding company reorganization in which CytoDyn Inc. (\"Old CytoDyn\") merged with and into a wholly-owned subsidiary of Point NewCo Inc. (which has been renamed CytoDyn Inc.) (\"New CytoDyn\") with Old CytoDyn continuing as the surviving corporation and as a wholly-owned subsidiary of New CytoDyn (the \"Holding Company Reorganization\"). In the Holding Company Reorganization, each outstanding share of Old CytoDyn capital stock (including common stock and Series B preferred stock) was disposed of in exchange for an equivalent share of New CytoDyn capital stock, and each Old CytoDyn warrant, convertible promissory note and stock option was converted into an equivalent right to purchase New CytoDyn common stock."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"In connection with the transactions consummated on November 16, 2018, immediately after the effective time of the Holding Company Reorganization, New CytoDyn issued to ProstaGene, LLC 27,000,000 newly issued shares of New CytoDyn common stock (representing approximately 6.5% of the total number of outstanding shares of New CytoDyn common stock, after giving effect to such issuance)."}],"balance_after":0,"derivative":{"exercise_price":0.57,"exercise_date":"2018-09-01","expiration_date":"2027-06-01","underlying":"Common Stock","underlying_shares":75000},"source":{"system":"sec-edgar","filing":"0000899243-18-029192","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1175680/000089924318029192/doc4.xml","form_type":"4"}},{"id":3762693,"issuer":{"id":5856,"kind":"organization","name":"CytoDyn Inc."},"owners":[{"id":22219,"kind":"person","name":"Gould Gregory A","position":1,"cik":"0001252905","reported_name":"Gould Gregory A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Options (right to buy)","published_at":"2018-11-16T23:32:59.000Z","date":"2018-11-16","kind":"disposition_to_issuer","acquired":false,"shares":100000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On November 16, 2018, CytoDyn Inc. completed a holding company reorganization in which CytoDyn Inc. (\"Old CytoDyn\") merged with and into a wholly-owned subsidiary of Point NewCo Inc. (which has been renamed CytoDyn Inc.) (\"New CytoDyn\") with Old CytoDyn continuing as the surviving corporation and as a wholly-owned subsidiary of New CytoDyn (the \"Holding Company Reorganization\"). In the Holding Company Reorganization, each outstanding share of Old CytoDyn capital stock (including common stock and Series B preferred stock) was disposed of in exchange for an equivalent share of New CytoDyn capital stock, and each Old CytoDyn warrant, convertible promissory note and stock option was converted into an equivalent right to purchase New CytoDyn common stock."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"In connection with the transactions consummated on November 16, 2018, immediately after the effective time of the Holding Company Reorganization, New CytoDyn issued to ProstaGene, LLC 27,000,000 newly issued shares of New CytoDyn common stock (representing approximately 6.5% of the total number of outstanding shares of New CytoDyn common stock, after giving effect to such issuance)."}],"balance_after":0,"derivative":{"exercise_price":0.68,"exercise_date":"2017-11-17","expiration_date":"2026-11-17","underlying":"Common Stock","underlying_shares":100000},"source":{"system":"sec-edgar","filing":"0000899243-18-029192","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1175680/000089924318029192/doc4.xml","form_type":"4"}},{"id":3762692,"issuer":{"id":5856,"kind":"organization","name":"CytoDyn Inc."},"owners":[{"id":22219,"kind":"person","name":"Gould Gregory A","position":1,"cik":"0001252905","reported_name":"Gould Gregory A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Options (right to buy)","published_at":"2018-11-16T23:32:59.000Z","date":"2018-11-16","kind":"disposition_to_issuer","acquired":false,"shares":50000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On November 16, 2018, CytoDyn Inc. completed a holding company reorganization in which CytoDyn Inc. (\"Old CytoDyn\") merged with and into a wholly-owned subsidiary of Point NewCo Inc. (which has been renamed CytoDyn Inc.) (\"New CytoDyn\") with Old CytoDyn continuing as the surviving corporation and as a wholly-owned subsidiary of New CytoDyn (the \"Holding Company Reorganization\"). In the Holding Company Reorganization, each outstanding share of Old CytoDyn capital stock (including common stock and Series B preferred stock) was disposed of in exchange for an equivalent share of New CytoDyn capital stock, and each Old CytoDyn warrant, convertible promissory note and stock option was converted into an equivalent right to purchase New CytoDyn common stock."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"In connection with the transactions consummated on November 16, 2018, immediately after the effective time of the Holding Company Reorganization, New CytoDyn issued to ProstaGene, LLC 27,000,000 newly issued shares of New CytoDyn common stock (representing approximately 6.5% of the total number of outstanding shares of New CytoDyn common stock, after giving effect to such issuance)."}],"balance_after":0,"derivative":{"exercise_price":1.09,"exercise_date":"2017-06-01","expiration_date":"2026-06-01","underlying":"Common Stock","underlying_shares":50000},"source":{"system":"sec-edgar","filing":"0000899243-18-029192","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1175680/000089924318029192/doc4.xml","form_type":"4"}},{"id":3762691,"issuer":{"id":5856,"kind":"organization","name":"CytoDyn Inc."},"owners":[{"id":22219,"kind":"person","name":"Gould Gregory A","position":1,"cik":"0001252905","reported_name":"Gould Gregory A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Options (right to buy)","published_at":"2018-11-16T23:32:59.000Z","date":"2018-11-16","kind":"disposition_to_issuer","acquired":false,"shares":50000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On November 16, 2018, CytoDyn Inc. completed a holding company reorganization in which CytoDyn Inc. (\"Old CytoDyn\") merged with and into a wholly-owned subsidiary of Point NewCo Inc. (which has been renamed CytoDyn Inc.) (\"New CytoDyn\") with Old CytoDyn continuing as the surviving corporation and as a wholly-owned subsidiary of New CytoDyn (the \"Holding Company Reorganization\"). In the Holding Company Reorganization, each outstanding share of Old CytoDyn capital stock (including common stock and Series B preferred stock) was disposed of in exchange for an equivalent share of New CytoDyn capital stock, and each Old CytoDyn warrant, convertible promissory note and stock option was converted into an equivalent right to purchase New CytoDyn common stock."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"In connection with the transactions consummated on November 16, 2018, immediately after the effective time of the Holding Company Reorganization, New CytoDyn issued to ProstaGene, LLC 27,000,000 newly issued shares of New CytoDyn common stock (representing approximately 6.5% of the total number of outstanding shares of New CytoDyn common stock, after giving effect to such issuance)."}],"balance_after":0,"derivative":{"exercise_price":0.975,"exercise_date":"2016-09-01","expiration_date":"2025-06-01","underlying":"Common Stock","underlying_shares":50000},"source":{"system":"sec-edgar","filing":"0000899243-18-029192","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1175680/000089924318029192/doc4.xml","form_type":"4"}},{"id":3762690,"issuer":{"id":5856,"kind":"organization","name":"CytoDyn Inc."},"owners":[{"id":22219,"kind":"person","name":"Gould Gregory A","position":1,"cik":"0001252905","reported_name":"Gould Gregory A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Options (right to buy)","published_at":"2018-11-16T23:32:59.000Z","date":"2018-11-16","kind":"disposition_to_issuer","acquired":false,"shares":25000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On November 16, 2018, CytoDyn Inc. completed a holding company reorganization in which CytoDyn Inc. (\"Old CytoDyn\") merged with and into a wholly-owned subsidiary of Point NewCo Inc. (which has been renamed CytoDyn Inc.) (\"New CytoDyn\") with Old CytoDyn continuing as the surviving corporation and as a wholly-owned subsidiary of New CytoDyn (the \"Holding Company Reorganization\"). In the Holding Company Reorganization, each outstanding share of Old CytoDyn capital stock (including common stock and Series B preferred stock) was disposed of in exchange for an equivalent share of New CytoDyn capital stock, and each Old CytoDyn warrant, convertible promissory note and stock option was converted into an equivalent right to purchase New CytoDyn common stock."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"In connection with the transactions consummated on November 16, 2018, immediately after the effective time of the Holding Company Reorganization, New CytoDyn issued to ProstaGene, LLC 27,000,000 newly issued shares of New CytoDyn common stock (representing approximately 6.5% of the total number of outstanding shares of New CytoDyn common stock, after giving effect to such issuance)."}],"balance_after":0,"derivative":{"exercise_price":1.55,"exercise_date":"2013-06-01","expiration_date":"2022-06-01","underlying":"Common Stock","underlying_shares":25000},"source":{"system":"sec-edgar","filing":"0000899243-18-029192","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1175680/000089924318029192/doc4.xml","form_type":"4"}},{"id":3762689,"issuer":{"id":5856,"kind":"organization","name":"CytoDyn Inc."},"owners":[{"id":22219,"kind":"person","name":"Gould Gregory A","position":1,"cik":"0001252905","reported_name":"Gould Gregory A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Options (right to buy)","published_at":"2018-11-16T23:32:59.000Z","date":"2018-11-16","kind":"disposition_to_issuer","acquired":false,"shares":50000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On November 16, 2018, CytoDyn Inc. completed a holding company reorganization in which CytoDyn Inc. (\"Old CytoDyn\") merged with and into a wholly-owned subsidiary of Point NewCo Inc. (which has been renamed CytoDyn Inc.) (\"New CytoDyn\") with Old CytoDyn continuing as the surviving corporation and as a wholly-owned subsidiary of New CytoDyn (the \"Holding Company Reorganization\"). In the Holding Company Reorganization, each outstanding share of Old CytoDyn capital stock (including common stock and Series B preferred stock) was disposed of in exchange for an equivalent share of New CytoDyn capital stock, and each Old CytoDyn warrant, convertible promissory note and stock option was converted into an equivalent right to purchase New CytoDyn common stock."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"In connection with the transactions consummated on November 16, 2018, immediately after the effective time of the Holding Company Reorganization, New CytoDyn issued to ProstaGene, LLC 27,000,000 newly issued shares of New CytoDyn common stock (representing approximately 6.5% of the total number of outstanding shares of New CytoDyn common stock, after giving effect to such issuance)."}],"balance_after":0,"derivative":{"exercise_price":2,"exercise_date":"2012-08-08","expiration_date":"2021-08-08","underlying":"Common Stock","underlying_shares":50000},"source":{"system":"sec-edgar","filing":"0000899243-18-029192","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1175680/000089924318029192/doc4.xml","form_type":"4"}},{"id":3762688,"issuer":{"id":5856,"kind":"organization","name":"CytoDyn Inc."},"owners":[{"id":22219,"kind":"person","name":"Gould Gregory A","position":1,"cik":"0001252905","reported_name":"Gould Gregory A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Options (right to buy)","published_at":"2018-11-16T23:32:59.000Z","date":"2018-11-16","kind":"disposition_to_issuer","acquired":false,"shares":50000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On November 16, 2018, CytoDyn Inc. completed a holding company reorganization in which CytoDyn Inc. (\"Old CytoDyn\") merged with and into a wholly-owned subsidiary of Point NewCo Inc. (which has been renamed CytoDyn Inc.) (\"New CytoDyn\") with Old CytoDyn continuing as the surviving corporation and as a wholly-owned subsidiary of New CytoDyn (the \"Holding Company Reorganization\"). In the Holding Company Reorganization, each outstanding share of Old CytoDyn capital stock (including common stock and Series B preferred stock) was disposed of in exchange for an equivalent share of New CytoDyn capital stock, and each Old CytoDyn warrant, convertible promissory note and stock option was converted into an equivalent right to purchase New CytoDyn common stock."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"In connection with the transactions consummated on November 16, 2018, immediately after the effective time of the Holding Company Reorganization, New CytoDyn issued to ProstaGene, LLC 27,000,000 newly issued shares of New CytoDyn common stock (representing approximately 6.5% of the total number of outstanding shares of New CytoDyn common stock, after giving effect to such issuance)."}],"balance_after":0,"derivative":{"exercise_price":0.66,"exercise_date":"2015-06-01","expiration_date":"2019-06-01","underlying":"Common Stock","underlying_shares":50000},"source":{"system":"sec-edgar","filing":"0000899243-18-029192","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1175680/000089924318029192/doc4.xml","form_type":"4"}},{"id":3762687,"issuer":{"id":5856,"kind":"organization","name":"CytoDyn Inc."},"owners":[{"id":22219,"kind":"person","name":"Gould Gregory A","position":1,"cik":"0001252905","reported_name":"Gould Gregory A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2018-11-16T23:32:59.000Z","date":"2018-11-16","kind":"disposition_to_issuer","acquired":false,"shares":19176,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On November 16, 2018, CytoDyn Inc. completed a holding company reorganization in which CytoDyn Inc. (\"Old CytoDyn\") merged with and into a wholly-owned subsidiary of Point NewCo Inc. (which has been renamed CytoDyn Inc.) (\"New CytoDyn\") with Old CytoDyn continuing as the surviving corporation and as a wholly-owned subsidiary of New CytoDyn (the \"Holding Company Reorganization\"). In the Holding Company Reorganization, each outstanding share of Old CytoDyn capital stock (including common stock and Series B preferred stock) was disposed of in exchange for an equivalent share of New CytoDyn capital stock, and each Old CytoDyn warrant, convertible promissory note and stock option was converted into an equivalent right to purchase New CytoDyn common stock."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"In connection with the transactions consummated on November 16, 2018, immediately after the effective time of the Holding Company Reorganization, New CytoDyn issued to ProstaGene, LLC 27,000,000 newly issued shares of New CytoDyn common stock (representing approximately 6.5% of the total number of outstanding shares of New CytoDyn common stock, after giving effect to such issuance)."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0000899243-18-029192","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1175680/000089924318029192/doc4.xml","form_type":"4"}},{"id":3897811,"issuer":{"id":5856,"kind":"organization","name":"CytoDyn Inc."},"owners":[{"id":22219,"kind":"person","name":"Gould Gregory A","position":1,"cik":"0001252905","reported_name":"Gould Gregory A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Options (right to buy)","published_at":"2018-06-12T21:55:15.000Z","date":"2018-06-08","kind":"grant","acquired":true,"shares":100000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The options will vest in four equal quarterly installments commencing on September 1, 2018."}],"balance_after":100000,"derivative":{"exercise_price":0.49,"expiration_date":"2028-06-08","underlying":"Common Stock","underlying_shares":100000},"source":{"system":"sec-edgar","filing":"0000899243-18-016229","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1175680/000089924318016229/doc4.xml","form_type":"4"}},{"id":4053921,"issuer":{"id":5856,"kind":"organization","name":"CytoDyn Inc."},"owners":[{"id":22219,"kind":"person","name":"Gould Gregory A","position":1,"cik":"0001252905","reported_name":"Gould Gregory A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Options (right to buy)","published_at":"2018-02-16T23:00:48.000Z","date":"2018-02-15","kind":"grant","acquired":true,"shares":50000,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":50000,"derivative":{"exercise_price":0.8,"exercise_date":"2018-02-15","expiration_date":"2023-06-01","underlying":"Common Stock","underlying_shares":50000},"source":{"system":"sec-edgar","filing":"0000899243-18-004434","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1175680/000089924318004434/doc4.xml","form_type":"4"}},{"id":4053920,"issuer":{"id":5856,"kind":"organization","name":"CytoDyn Inc."},"owners":[{"id":22219,"kind":"person","name":"Gould Gregory A","position":1,"cik":"0001252905","reported_name":"Gould Gregory A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Options (right to buy)","published_at":"2018-02-16T23:00:48.000Z","date":"2018-02-15","kind":"disposition_to_issuer","acquired":false,"shares":50000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Such options were fully vested and exercisable as of the date of the reported transactions."}],"balance_after":0,"derivative":{"exercise_price":0.8,"expiration_date":"2018-06-01","underlying":"Common Stock","underlying_shares":50000},"source":{"system":"sec-edgar","filing":"0000899243-18-004434","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1175680/000089924318004434/doc4.xml","form_type":"4"}},{"id":4069681,"issuer":{"id":5856,"kind":"organization","name":"CytoDyn Inc."},"owners":[{"id":22219,"kind":"person","name":"Gould Gregory A","position":1,"cik":"0001252905","reported_name":"Gould Gregory A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Options (right to buy)","published_at":"2018-02-10T01:06:47.000Z","date":"2018-02-07","kind":"grant","acquired":true,"shares":160662,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On February 7, 2018, the board of directors of CytoDyn Inc. approved an amendment to its director compensation program, providing for payment in stock options, in lieu of cash, of all unpaid director retainer fees for the four-quarter period ending February 28, 2018. The number of options awarded to each director was determined by applying a price of $0.31 per option, which was the fair value estimate of the option award as of the grant date, using the Black-Scholes option pricing model."}],"balance_after":160662,"derivative":{"exercise_price":0.56,"exercise_date":"2018-02-07","expiration_date":"2028-02-07","underlying":"Common Stock","underlying_shares":160662},"source":{"system":"sec-edgar","filing":"0000899243-18-003462","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1175680/000089924318003462/doc4.xml","form_type":"4"}},{"id":4294817,"issuer":{"id":5856,"kind":"organization","name":"CytoDyn Inc."},"owners":[{"id":22219,"kind":"person","name":"Gould Gregory A","position":1,"cik":"0001252905","reported_name":"Gould Gregory A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Options (right to buy)","published_at":"2017-06-05T20:45:03.000Z","date":"2017-06-01","kind":"grant","acquired":true,"shares":75000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Subject to stockholder approval, at the next annual meeting, of the increase in the number of shares of common stock authorized for issuance under the CytoDyn Inc. 2012 Equity Incentive Plan, as amended, the options will vest in four equal quarterly installments commencing on September 1, 2017."}],"balance_after":75000,"derivative":{"exercise_price":0.57,"expiration_date":"2027-06-01","underlying":"Common Stock","underlying_shares":75000},"source":{"system":"sec-edgar","filing":"0000899243-17-015349","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1175680/000089924317015349/doc4.xml","form_type":"4"}},{"id":4379451,"issuer":{"id":7560,"kind":"organization","name":"AYTU BIOPHARMA, INC"},"owners":[{"id":22219,"kind":"person","name":"Gould Gregory A","position":1,"cik":"0001252905","reported_name":"Gould Gregory A","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Employee Stock Option Grant","published_at":"2017-03-17T20:25:40.000Z","date":"2017-03-16","kind":"grant","acquired":true,"shares":25000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F4","text":"These four transactions involved an amendment of the exercise price of an outstanding option, resulting in the deemed cancellation of the \"old\" option and the grant of a replacement option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"33.3% vests on the one year, two year and three year anniversary of the date of grant, subject to the Grantee's service as an employee on such dates."}],"balance_after":25000,"derivative":{"exercise_price":0.82,"expiration_date":"2026-07-07","underlying":"Common Stock","underlying_shares":25000},"source":{"system":"sec-edgar","filing":"0001638599-17-000297","document":"doc4_4625.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1252905/000163859917000297/doc4_4625.xml","form_type":"4"}},{"id":4379450,"issuer":{"id":7560,"kind":"organization","name":"AYTU BIOPHARMA, INC"},"owners":[{"id":22219,"kind":"person","name":"Gould Gregory A","position":1,"cik":"0001252905","reported_name":"Gould Gregory A","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Employee Stock Option Grant","published_at":"2017-03-17T20:25:40.000Z","date":"2017-03-16","kind":"grant","acquired":true,"shares":20834,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F4","text":"These four transactions involved an amendment of the exercise price of an outstanding option, resulting in the deemed cancellation of the \"old\" option and the grant of a replacement option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"These options are 100% vested."}],"balance_after":20834,"derivative":{"exercise_price":0.82,"expiration_date":"2015-11-11","underlying":"Common Stock","underlying_shares":20834},"source":{"system":"sec-edgar","filing":"0001638599-17-000297","document":"doc4_4625.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1252905/000163859917000297/doc4_4625.xml","form_type":"4"}},{"id":4379449,"issuer":{"id":7560,"kind":"organization","name":"AYTU BIOPHARMA, INC"},"owners":[{"id":22219,"kind":"person","name":"Gould Gregory A","position":1,"cik":"0001252905","reported_name":"Gould Gregory A","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Employee Stock Option Grant","published_at":"2017-03-17T20:25:40.000Z","date":"2017-03-16","kind":"disposition_to_issuer","acquired":false,"shares":25000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F4","text":"These four transactions involved an amendment of the exercise price of an outstanding option, resulting in the deemed cancellation of the \"old\" option and the grant of a replacement option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"33.3% vests on the one year, two year and three year anniversary of the date of grant, subject to the Grantee's service as an employee on such dates."}],"balance_after":0,"derivative":{"exercise_price":3.23,"expiration_date":"2026-07-07","underlying":"Common Stock","underlying_shares":25000},"source":{"system":"sec-edgar","filing":"0001638599-17-000297","document":"doc4_4625.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1252905/000163859917000297/doc4_4625.xml","form_type":"4"}},{"id":4379448,"issuer":{"id":7560,"kind":"organization","name":"AYTU BIOPHARMA, INC"},"owners":[{"id":22219,"kind":"person","name":"Gould Gregory A","position":1,"cik":"0001252905","reported_name":"Gould Gregory A","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Employee Stock Option Grant","published_at":"2017-03-17T20:25:40.000Z","date":"2017-03-16","kind":"disposition_to_issuer","acquired":false,"shares":20834,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F4","text":"These four transactions involved an amendment of the exercise price of an outstanding option, resulting in the deemed cancellation of the \"old\" option and the grant of a replacement option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"These options are 100% vested."}],"balance_after":0,"derivative":{"exercise_price":3.23,"expiration_date":"2015-11-11","underlying":"Common Stock","underlying_shares":20834},"source":{"system":"sec-edgar","filing":"0001638599-17-000297","document":"doc4_4625.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1252905/000163859917000297/doc4_4625.xml","form_type":"4"}},{"id":4413528,"issuer":{"id":7560,"kind":"organization","name":"AYTU BIOPHARMA, INC"},"owners":[{"id":22219,"kind":"person","name":"Gould Gregory A","position":1,"cik":"0001252905","reported_name":"Gould Gregory A","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Warrant to Purchase Common Stock","published_at":"2017-03-02T00:33:56.000Z","date":"2017-02-27","kind":"exercise","acquired":false,"shares":66666,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":0,"derivative":{"exercise_price":1.86,"exercise_date":"2017-11-02","expiration_date":"2021-11-02","underlying":"Common Stock","underlying_shares":66666},"source":{"system":"sec-edgar","filing":"0001638599-17-000235","document":"doc4_4576.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1252905/000163859917000235/doc4_4576.xml","form_type":"4"}},{"id":4413527,"issuer":{"id":7560,"kind":"organization","name":"AYTU BIOPHARMA, INC"},"owners":[{"id":22219,"kind":"person","name":"Gould Gregory A","position":1,"cik":"0001252905","reported_name":"Gould Gregory A","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2017-03-02T00:33:56.000Z","date":"2017-02-27","kind":"exercise","acquired":true,"shares":66666,"price":0.75,"value":49999.5,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Of these shares, 165,000 shares are restricted shares that vest on July 7, 2026, subject to earlier vesting in certain situations."}],"balance_after":340231,"source":{"system":"sec-edgar","filing":"0001638599-17-000235","document":"doc4_4576.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1252905/000163859917000235/doc4_4576.xml","form_type":"4"}},{"id":4548136,"issuer":{"id":5856,"kind":"organization","name":"CytoDyn Inc."},"owners":[{"id":22219,"kind":"person","name":"Gould Gregory A","position":1,"cik":"0001252905","reported_name":"Gould Gregory A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2016-11-21T21:48:23.000Z","date":"2016-11-17","kind":"grant","acquired":true,"shares":100000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests 25% on the date of grant and the remaining 75% in equal monthly installments over the next year."}],"balance_after":100000,"derivative":{"exercise_price":0.68,"expiration_date":"2026-11-17","underlying":"Common Stock","underlying_shares":100000},"source":{"system":"sec-edgar","filing":"0000899243-16-034017","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1175680/000089924316034017/doc4.xml","form_type":"4"}},{"id":4566436,"issuer":{"id":7560,"kind":"organization","name":"AYTU BIOPHARMA, INC"},"owners":[{"id":22219,"kind":"person","name":"Gould Gregory A","position":1,"cik":"0001252905","reported_name":"Gould Gregory A","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Warrant to Purchase Common Stock","published_at":"2016-11-04T20:58:00.000Z","date":"2016-11-02","kind":"purchase","acquired":true,"shares":66666,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The shares of stock and warrants were purchased at a purchase price per unit of $1.50."}],"balance_after":66666,"derivative":{"exercise_price":1.86,"exercise_date":"2017-11-02","expiration_date":"2021-11-02","underlying":"Common Stock","underlying_shares":66666},"source":{"system":"sec-edgar","filing":"0001638599-16-001508","document":"doc4_4277.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1252905/000163859916001508/doc4_4277.xml","form_type":"4"}},{"id":4566435,"issuer":{"id":7560,"kind":"organization","name":"AYTU BIOPHARMA, INC"},"owners":[{"id":22219,"kind":"person","name":"Gould Gregory A","position":1,"cik":"0001252905","reported_name":"Gould Gregory A","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2016-11-04T20:58:00.000Z","date":"2016-11-02","kind":"purchase","acquired":true,"shares":66666,"price":1.5,"value":99999.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The shares of stock and warrants were purchased at a purchase price per unit of $1.50."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Of these shares, 165,000 shares are restricted shares that vest on July 7, 2026, subject to earlier vesting in certain situations."}],"balance_after":273565,"source":{"system":"sec-edgar","filing":"0001638599-16-001508","document":"doc4_4277.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1252905/000163859916001508/doc4_4277.xml","form_type":"4"}}]}